Latest Conference Articles

LITESPARK-013 Data Support RP2D of Belzutifan as Standard Option in Advanced ccRCC

Administration of the hypoxia-inducible factor–2α inhibitor belzutifan (Welireg) at the recommended phase 2 dose of 120 mg daily produced comparable toxicities and efficacy outcomes to that of a daily 200-mg dose of the agent in patients with advanced clear cell renal cell carcinoma.

Dr Zakharia on Real-World Outcomes With First-Line Axitinib Plus Pembrolizumab in RCC

Yousef Zakharia, MD, discusses the real-world treatment outcomes of first-line axitinib plus pembrolizumab in patients with advanced renal cell carcinoma based on International Metastatic RCC Database Consortium risk score.

Zanzalintinib Continues to Elicit Efficacy With Tolerability in Advanced ccRCC

Treatment with zanzalintinib monotherapy produced antitumor activity and was well tolerated in patients with previously treated advanced clear cell renal cell carcinoma.

Considering the Data Behind Belzutifan's Approval in VHL Disease–Associated Cancers

Jaleh Fallah, MD, discusses the FDA's evaluation of data from the phase 2 LITESPARK-004 trial, which supported the approval of belzutifan in von Hippel-Lindau–associated cancers.

Dr Pal on Outcomes With the Use of Zanzalintinib in Relapsed/Refractory ccRCC

Sumanta Kumar Pal, MD, FASCO, discusses outcomes with the use of zanzalintinib in patients with relapsed/refractory clear cell renal cell carcinoma.

Multimodal Care Marks the Past, Present, and Future of Localized Breast Cancer Management

Improvements in screening, systemic therapy, and precision medicine have reduced breast cancer mortality and morbidity, and further progress will hinge on the use of ctDNA and CTCs for disease monitoring, continued development of novel antiestrogenic agents, and movement of ADCs and immunotherapy into expanded settings and indications.

Dr Scher on the Importance of Molecular Testing in Prostate Cancer

Howard I. Scher, MD, discusses the evolution of molecular testing mechanisms in patients with prostate cancer and highlights the importance of making patient-centered decisions based on test results.

Reflecting on Advances Made in High-Risk, Low-Grade Prostate Cancer Management

Howard I. Scher, MD, sheds light on various research programs he has led or has been heavily involved with that have helped change the course of prostate cancer treatment over the years.

Dr Jhaveri on the Evolution of Endocrine Therapy in ER+ Metastatic Breast Cancer

Komal Jhaveri , MD, FACP, discusses the rationale behind the ongoing clinical development of elacestrant and other endocrine therapies in patients with estrogen receptor–positive metastatic breast cancer.

Enfortumab Vedotin Plus Pembrolizumab Has Potential to Alter SOC in Frontline Urothelial Cancer

The combination of enfortumab vedotin-ejfv plus pembrolizumab represents a chemotherapy-free regimen that could alter the standard of care in the frontline treatment of all patients with metastatic urothelial carcinoma.

Dr Braun on the Clinical Implications of the CONTACT-03 Trial in RCC

David Braun, MD, PhD, discusses the findings from the phase 3 CONTACT-03 trial investigating immunotherapy rechallenge in patients with renal cell carcinoma and the implications of these findings on the RCC treatment paradigm.

Treatments for Translocation RCC Require Novel Therapeutic Targets

Immune checkpoint inhibitors have been associated with improved outcomes for patients with metastatic translocation renal cell carcinoma; however, novel therapies and therapeutic targets are needed for patients within this histologic subset.

Dr Tremblay on the Identification and Prevalence of MDS/MPN Overlap Syndromes

Douglas A. Tremblay, MD, discusses the prevalence of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes and the evolving treatment paradigm for these diseases.

Pursuit of Effective Agents Continues in Multiple Types of Sarcomas

Research has continued to focus on developing novel therapies and bringing new treatments to the sarcoma treatment paradigm.

Unique Molecular Profiles of Biliary Tract Cancers Drive Continued Development of Targeted Therapies

The mitigation and management of toxicities is a key component of treating patients with biliary tract cancers with targeted therapies.

Dr Braunstein on Stem Cell Transplant Eligibility Criteria in Multiple Myeloma

Dr Markman on Pragmatic Clinical Trial Designs in Ovarian Cancer

Maurie Markman, MD, discusses the importance of designing clinical trials for patients with ovarian cancer that are based on real-world data and consider the increasing complexity of treatment sequencing in this disease.

Markman Underscores Unanswered Questions in Ovarian Cancer Management

Although advancements were “simple” to track for more than 40 years and left few questions open for evaluation in the ovarian cancer treatment paradigm, new questions have begun to develop surrounding the complexity of care.

Recent Clinical Trial Updates Shift DLBCL Treatment Paradigm

Gilles Salles, MD, PhD, expands on how data from recent clinical trials have helped shift the treatment paradigm for patients with diffuse large B-cell lymphoma.

Lamanna Details Evolution of CLL Treatment Following Resistance

Nicole Lamanna, MD, discusses treatment options for patients with chronic lymphocytic leukemia who develop resistance to a prior treatment.

Data Continue to Refine Frontline BTK Inhibitor Selection in CLL

Along with the combination of venetoclax and obinutuzumab, the BTK inhibitor–based regimens of zanubrutinib monotherapy and acalabrutinib plus obinutuzumab represent the preferred options in the National Comprehensive Cancer Network Guidelines for the first-line treatment of patients with chronic lymphocytic leukemia without 17p deletions or TP53 mutations.

Dr Henderson on Incorporating Immunotherapy Agents into Practice in Bladder Cancer

R. Jonathan Henderson, MD, discusses incorporating immunotherapy agents into practice in patients with bladder cancer.

Dr Lowentritt on the Exploration of Active Surveillance in Prostate Cancer

Benjamin H. Lowentritt, MD, FACS, discusses the exploration of active surveillance in patients with prostate cancer.

Dr Morris on Active Surveillance in Low- and Intermediate-Risk Patients With Prostate Cancer

David Morris, MD, FACS, discusses the best practices for active surveillance in low- and intermediate-risk patients with prostate cancer, highlighting factors to look for in patients undergoing active surveillance that may point to the need for further treatment.

Dr Crawford on the Evolving Role of Active Surveillance in Prostate Cancer

E. David Crawford, MD, discusses the evolving role of active surveillance in patients with prostate cancer.

Role of Radiation Continues to Grow in the Treatment of Prostate Cancer

Improved toxicity, advanced technology, and novel techniques have helped increase the use of radiotherapy for the treatment of different subgroups of patients with prostate cancer.

Strategic Active Surveillance Methods Drive Patient-Focused Prostate Cancer Care

Active surveillance can provide eligible patients with low-risk prostate cancer the opportunity to defer or avoid treatment and instead opt for routine monitoring of their disease; however, challenges arise when determining which patients should be eligible for this approach and how to maintain patient and provider protocol compliance.

Genomics Help Drive Active Surveillance Decisions in Low-Risk Prostate Cancer

David Morris, MD, FACS, discusses the increasing the use of active surveillance in patients with low-risk prostate cancer and the goals of avoiding adverse effects associated with possible therapies.

Dr Jayram on the Role of Immunotherapy in Bladder Cancer

Gautam Jayram, MD, discusses the current indications for immunotherapy agents in the bladder cancer treatment paradigm, as well as immune-related adverse effects to be aware of when treating patients who are receiving these therapies.

Bladder Cancer Programs Offer Patients Comprehensive and Cutting-Edge Care

Gautam Jayram, MD, discusses current standards of care in the bladder cancer treatment arena, novel therapies under investigation in clinical trials that may expand the arsenal of available treatment strategies, and emphasizes the importance of implementing bladder cancer programs.